CD8

[Journal of Clinical Investigation] Scientists found that CD4+ Tfh TIL, CD8+ TIL and TIL-B, co-localizing in TLS, all expressed the CXCL13 receptor CXCR5.

[Cancer Cell] Researchers compared the efficacies of sequential and/or combinatorial regimens in subcutaneous murine models of melanoma driven by BrafV600, Nras, or Nf1 mutations as well as colorectal and pancreatic carcinoma driven by KrasG12C.

[Acta Neuropathologica Communications] In mouse models, investigators assessed whether dextran sodium sulfate-mediated colitis could exert lingering effects on dopaminergic pathways in the brain and whether colitis increased vulnerability to a subsequent exposure to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

[Pharmacological Research] The antitumour activity of lenvatinib in immunocompetent and immunodeficient mice was compared to determine the role of T cell immunity. The antitumour activity of T cells was analysed by cytokine production and adoptive T cell therapy.

[Journal of Immunology] Scientists examined the cellular and molecular elements that promote CD8-to-CD4 lineage conversion and the development of CI-Treg cells in mice.

[BriaCell Therapeutics Corp.] BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, jointly announced a multi-year, non-exclusive license agreement with ImaginAb Inc., a biotechnology company focused on developing next-generation immuno oncology imaging agents and radiopharmaceutical therapies.